semaglutide .25 Oral Wegovy approved for obesity management by FDA on December 23, 2025 Formulation: High‑dose oral (25 mg daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) Semaglutide is similar to a natural hormone in your body (incretin) Wegovy Pill: First Oral GLP-1

It is important to distinguish between simple muscle soreness and signs of a more serious underlying condition

Most conventional physicians doubt that too much of a particular yeast can cause the digestive and cognitive issues Delaney experienced, even as conditions such as thrush, diaper rash, and vaginal yeast infections are commonly attributed to yeast overgrowth

Make sure to use it exactly as directed, and dont use more or less than prescribed without first consulting your doctor

Other payers who dropped GLP-1 coverage for weight loss this year include Harvard Pilgrim Health Care, Blue Cross Blue Shield of Michigan, and North Carolinas Medicaid program